B of A Securities Maintains Buy on Vaxcyte, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has maintained a Buy rating on Vaxcyte (NASDAQ:PCVX) and increased the price target from $67 to $80. This adjustment reflects a positive outlook on the company's stock, suggesting potential upside from its current trading level.
January 02, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxcyte's stock may experience a positive short-term impact due to B of A Securities analyst Jason Gerberry maintaining a Buy rating and raising the price target to $80.
Analyst ratings and price target adjustments are significant indicators for investors, often leading to short-term price movements. The increase in Vaxcyte's price target by a reputable analyst from B of A Securities suggests a strong conviction in the company's future performance, which could lead to increased investor confidence and a rise in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100